Tirzepatide Once Weekly for the Treatment of Obesity

Article Medicine, General & Internal

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial

Dominik Dahl et al.

Summary: The addition of tirzepatide to insulin glargine treatment in patients with type 2 diabetes resulted in significant improvements in glycemic control after 40 weeks.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Medicine, General & Internal

Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis

Ali Aminian et al.

Summary: Among patients with NASH and obesity, bariatric surgery was associated with a significantly lower risk of incident major adverse liver outcomes and MACE compared with nonsurgical management.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato et al.

Summary: In this study comparing Tirzepatide and glargine in patients with type 2 diabetes inadequately controlled on oral glucose-lowering medications, Tirzepatide demonstrated greater reduction in HbA(1c) and lower incidence of hypoglycemia at week 52, with no excess cardiovascular risk observed compared to glargine.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial

Thomas A. Wadden et al.

Summary: This study compared the effects of once-weekly subcutaneous semaglutide with placebo as an adjunct to intensive behavioral therapy and initial low-calorie diet for weight management in adults with overweight or obesity. The results showed that semaglutide led to significantly greater weight loss compared to placebo over 68 weeks, with a higher proportion of participants achieving weight loss goals. More research is needed to evaluate the long-term effectiveness of this treatment.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial

Melanie Davies et al.

Summary: In this study, once-weekly subcutaneous semaglutide 2.4 mg was shown to achieve a significantly greater and clinically meaningful weight reduction compared to placebo in adults with overweight or obesity and type 2 diabetes. Adverse events, particularly gastrointestinal events, were more common with semaglutide compared to placebo.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P. H. Wilding et al.

Summary: The study demonstrates that for individuals with obesity, once-weekly use of 2.4 mg semaglutide in combination with lifestyle intervention can lead to sustained and clinically relevant weight loss, with significant improvements in cardiometabolic risk factors and physical functioning reported by participants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial

Domenica Rubino et al.

Summary: Continuing treatment with semaglutide resulted in greater weight loss maintenance and improvement in other physical indicators compared to switching to placebo over a 48-week period in adults with overweight or obesity. The study also found that gastrointestinal events were more common with continued semaglutide, but discontinuation rates were similar between the two groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Describing the Weight-Reduced State: Physiology, Behavior, and Interventions

Louis J. Aronne et al.

Summary: Although many individuals with obesity can lose weight through lifestyle therapy, successful long-term weight loss is difficult to achieve, with most people regaining the lost weight over time. The factors contributing to weight recidivism are unclear and complex, involving neurohormonal, physiological, and behavioral aspects. Various experts have discussed the physiological and behavioral factors, physical activity, and drug therapy in weight-loss maintenance at a workshop convened by the National Institute of Diabetes and Digestive and Kidney Diseases.

OBESITY (2021)

添加到收藏夹

Review Surgery

What Is Weight Loss After Bariatric Surgery Expressed in Percentage Total Weight Loss (%TWL)? A Systematic Review

Anne-Sophie Van Rijswijk et al.

Summary: Despite limited data, short-term weight loss results favor LRYGB over LSG. However, there is insufficient quality data on %TWL, especially for LSG. The use of %TWL as the primary outcome measure in bariatric surgery should be encouraged.

OBESITY SURGERY (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock et al.

Summary: Tirzepatide demonstrated significant improvements in glycemic control and body weight without increasing the risk of hypoglycemia. The safety profile was consistent with GLP-1 receptor agonists, suggesting a potential monotherapy use for the treatment of type 2 diabetes.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

Bernhard Ludvik et al.

Summary: The study aimed to compare the efficacy and safety of tirzepatide versus titrated insulin degludec in the treatment of type 2 diabetes. The results showed that tirzepatide had significant advantages in reducing HbA(1c) and bodyweight, and decreased the risk of hypoglycemia.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Juan P. Frias et al.

Summary: The study showed that Tirzepatide was both noninferior and superior to Semaglutide in terms of the mean change in glycated hemoglobin levels for patients with type 2 diabetes over 40 weeks. Additionally, reductions in body weight were greater with Tirzepatide compared to Semaglutide, with similar rates of gastrointestinal adverse events reported in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism